Galectin Therapeutics (Galectin Therapeutics) Market Cap

Galectin Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Market Cap							162.72	127.85	122.84	67.15	102.68

Galectin Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Market Cap																67.15	125.12	85.80	118.75	102.68

For the Biotechnology subindustry, Galectin Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Galectin Therapeutics's Market Cap falls into.

Galectin Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Galectin Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Galectin Therapeutics's Market Cap for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galectin Therapeutics  (NAS:GALT) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Galectin Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Galectin Therapeutics (Galectin Therapeutics) Business Description